For example, by promoting HCC cell proliferation by regulating the expression of β-catenin (eta-catenin) (133), USP9X is able to affect hepatoma cells with ARID1A mutations through the AMPK pathway (134), miR-26b can regulate USP9X-mediated p53 deubiquitination to enhance the sensitivity of HCC cells to doxorubicin (135), miR-26b is also able to target USP9X expression to suppress EMT in hepatocytes (136), and usp9x can affect the drug sensitivity of hepatoma cells to doxorubicin and WP1130 through p53 (137). This evidence concerns the gene TP53 and hepatocellular carcinoma.